BioNTech has 19.0% upside to the $104.93 analyst target and low leverage, but quality of 3.4 is below the 4.0 floor, the company burns cash and insiders have been selling.
Thesis pillars
- Analyst Target Upside→Stable
- Cash Burn Below Quality Floor→Stable
- Insider Selling Pressure↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026
BioNTech SE (BNTX) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $90.70: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial,... Read more
Sell if holding. Engine safety override at $90.70: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 51. Score 5.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 117d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — BioNTech SE
Latest news
- NEWS UBS Maintains Buy on BioNTech, Lowers Price Target to $125 — benzinga Nov 4, 2026 neutral
- NEWS Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106 — benzinga Nov 4, 2026 neutral
- NEWS Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment in Emvena Therapeutics — fiscal.ai Nov 4, 2026 neutral
- NEWS UBS Adjusts Price Target on BioNTech — fiscal.ai Nov 4, 2026 neutral
- NEWS Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125 — benzinga Nov 4, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:59:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Unprofitable operations — net margin -63.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $90.70: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 51. Prior stop was $85.40. Score 5.1/10, moderate confidence.
Analyst target: $105.28 (+16.1% upside). Prior stop was $85.40. Stop-loss: $85.40.
Quality below floor (3.4 < 4.0).
BioNTech SE trades at a P/E of N/A (forward -16.6). TrendMatrix value score: 6.3/10. Verdict: Sell.
29 analysts rate BNTX, with a consensus score of 3.9/5. 20 analysts publish price targets averaging $117.
What does BioNTech SE do?BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in...
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.